AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02086942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
Study NCT02086942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
Study NCT01845285 — intervention group
Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
Study NCT05723016 — intervention group
Intervention type: OTHER
Intervention: preimplantation genetic test for aneuploidies (PGT-a)
Description: preimplantation genetic test for embryo aneuploidies after IVF
Study NCT01991171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
Study NCT01991171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
Study NCT04112017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 360
Description: Hyaluronic acid
Study NCT01674231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grape in the form of freeze-dried whole grape powder
Description: 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
Study NCT01674231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grape powder placebo
Description: 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
Study NCT00736801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol and Salmeterol / Fluticasone
Description: Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
Study NCT03530475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound and doppler
Description: • Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion.
Study NCT02979743 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Occupational therapy
Study NCT02979743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Study NCT02979743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy puls acupuncture and massage methods
Study NCT00470392 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod
Description: Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
Study NCT00470392 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clobetasol
Description: Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
Study NCT04319354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of cfDNA
Description: Analysis of cfDNA through liquid biopsy
Study NCT04319354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of cfDNA
Description: Analysis of cfDNA through liquid biopsy
Study NCT03630653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel LN in breast cancer recurrence
Description: Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
Study NCT02186002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 10 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
Study NCT02186002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 50 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
Study NCT02186002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 200 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
Study NCT02186002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 500 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
Study NCT02186002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 1000 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
Study NCT02186002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 (Dose to be determined)
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
Study NCT02186002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01728025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study NCT00281203 — intervention group
Intervention type: PROCEDURE
Intervention: blood drawing
Description: blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
Study NCT00281203 — intervention group
Intervention type: PROCEDURE
Intervention: fiberoptic bronchoscopy
Description: A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
Study NCT02492529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological tests
Description: Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood
Study NCT02492529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood
Study NCT02492529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A cranial MRI
Study NCT02492529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental procedure
Study NCT02492529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental procedure
Study NCT03519568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 (inoculation vaccine)
Description: EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
Study NCT03519568 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 (inoculation vaccine)
Description: EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
Study NCT02052921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal resection
Description: Surgical rectal resection
Study NCT02052921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Study NCT00624533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDS Method (muscular chains physical therapy method)
Description: Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
Study NCT00624533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy in Primary Health Care
Description: Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks.
Study NCT00554437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UW Falls Prevention Program
Description: The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
Study NCT00554437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UW Falls Prevention Program
Description: The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
Study NCT01845792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel with Abiraterone Acetate
Description: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
Study NCT01845792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Cabazitaxel intravenously every 3 weeks
Study NCT01066988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ORB Ocular Emulsion
Description: lubricant eye drop
Study NCT01066988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SootheXP Emollient (Lubricant) Eye Drops
Description: lubricant eye drop
Study NCT02180334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
Study NCT02180334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin
Description: During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
Study NCT02180334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
Study NCT02180334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen (paracetamol)
Description: On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
Study NCT02180334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Description: On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
Study NCT03025828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHar
Description: for 6 months
Study NCT01498640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Description: up to three 0.58 mg injections
Study NCT03023085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: BLI4700 bowel preparation
Study NCT00850395 — intervention group
Intervention type: DRUG
Intervention: maraviroc
Description: No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
Study NCT03676530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro-Tec Shin Splint Compression Wrap
Description: EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
Study NCT02361255 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT00193882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2 IV day 1
Study NCT00193882 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 35 Gy in 15 fractions
Study NCT00193882 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 35 Gy in 15 fractions
Study NCT00193882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 800mg/m2/day IV days 1 - 4
Study NCT03447665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime routine
Description: Tailored bedtime routine
Study NCT03447665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep schedule
Description: Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
Study NCT03447665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (bedtime)
Description: Parents implement behavioral sleep intervention at bedtime.
Study NCT03447665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (after night wakings)
Description: Parents implement behavioral sleep intervention following each night waking.
Study NCT00477672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 10 mg, tablet, once daily by mouth, 6 weeks
Study NCT00477672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: 40 mg, tablet, once daily by mouth, 6 weeks
Study NCT00856544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Film coated tablet, 5 mg PO BID, 1 year
Study NCT00856544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Film coated tablet, 10 mg PO BID, 1 year
Study NCT00856544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated tablet, 1 tablet PO BID, 3-6 months
Study NCT00625781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart and Insulin human (isophane)
Description: Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
Study NCT02435927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001+ CAPOX (Oxaliplatin, capecitabine)
Description: ASLAN001 in combination with oxaliplatin and capecitabine
Study NCT02435927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001 + mFolfox6 (5-FU, leucovorin)
Description: ASLAN001 in combination with 5-FU and leucovorin
Study NCT03963427 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast reconstruction
Description: Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
Study NCT00477672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, once daily by mouth, 6 weeks
Study NCT02739269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum AMH measurement
Description: Serum AMH is measured one month before the IVF treatment
Study NCT02739269 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: AFC measurement
Description: Early follicular phase AFC is measured one month before the IVF treatment
Study NCT01914224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary education of low sodium and high potassium consumption
Study NCT01914224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary education of low sodium consumption only
Study NCT03806686 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline
Study NCT03806686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE
Description: ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
Study NCT01736696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 5 mg BID For 13 days and once on Day 14
Study NCT01736696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 10 mg BID for 13 days and once on Day 14\*
Study NCT01736696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 20 mg BID for 13 days and once on Day 14
Study NCT01736696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 30 mg BID for 13 days and once on Day 14
Study NCT01736696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 60 mg tablet once a day (QD) for 14 days
Study NCT01736696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 50 mg tablets two times a day (BID) for 13 days and once on day 14
Study NCT02386696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Lung ultrasound examination on healthy volunteers
Study NCT03289507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment1
Description: Longvida Capsule formulation A
Study NCT03289507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment2
Description: Longvida Capsule formulation B
Study NCT03289507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment3
Description: Curcuma longa extract of Rhizomes